Stocks of Gilead Sciences Inc. (NASDAQ:GILD) traded higher last session on Wall Street, down -0.81% to $75.88.
According to the data, Gilead Sciences Inc. (NASDAQ:GILD) has 30 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $116.00 and a low of $80.00, we find $90.00. Given the previous closing price of $76.50, this indicates a potential upside of 17.65 percent. GILD stock price is now -2.25% away from the 50-day moving average and -6.84% away from the 200-day moving average. The market capitalization of the company currently stands at $95.32B.
A total of 16 analysts have issued a hold rating and 13 have given it a buy rating. Brokers who have rated the stock have averaged $91.23 as their price target over the next twelve months.
With the price target reduced from $81 to $80, Barclays maintained Equal Weight rating for Gilead Sciences Inc. (NASDAQ: GILD).
In other news, Dickinson Andrew D, Chief Financial Officer sold 5,000 shares of the company’s stock on Jul 20. The stock was sold for $400,000 at an average price of $80.00. Upon completion of the transaction, the Chief Financial Officer now directly owns 107,587 shares in the company, valued at $8.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 28, 10% Owner GILEAD SCIENCES, INC. bought 1,010,000 shares of the business’s stock. A total of $19,452,600 was incurred on buying the stock at an average price of $19.26. This leaves the insider owning 14,823,029 shares of the company worth $1.12 billion. Insiders disposed of 230,852 shares of company stock worth roughly $17.52 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in GILD stock. A new stake in Gilead Sciences Inc. shares was purchased by PORTSIDE WEALTH GROUP, LLC during the first quarter worth $27,529,000. UNISUPER MANAGEMENT PTY LTD invested $23,840,000 in shares of GILD during the first quarter. In the first quarter, TWINBEECH CAPITAL LP acquired a new stake in Gilead Sciences Inc. valued at approximately $21,290,000. EXODUSPOINT CAPITAL MANAGEMENT, LP acquired a new stake in GILD for approximately $21,192,000. GENUS CAPITAL MANAGEMENT INC. purchased a new stake in GILD valued at around $11,510,000 in the second quarter. In total, there are 2,350 active investors with 83.00% ownership of the company’s stock.
Friday’s opening bell rang with an opening price of $76.55 for Gilead Sciences Inc. (NASDAQ: GILD). During the past 12 months, Gilead Sciences Inc. has had a low of $61.44 and a high of $89.74. As of last week, the company has a debt-to-equity ratio of 1.19, a current ratio of 1.00, and a quick ratio of 0.90. According to the stock market information, the enterprise value for the company is $113.13B, which is based on a 17.46 price-to-earnings ratio, a 4.99 price-to-earnings-growth ratio, and a beta of 0.38. The fifty day moving average price for GILD is $77.63 and a two-hundred day moving average price translates $81.44 for the stock.
The latest earnings results from Gilead Sciences Inc. (NASDAQ: GILD) was released for Jun, 2023. The net profit margin was 20.00% and return on equity was 26.00% for GILD. The company reported revenue of $6.6 billion for the quarter, compared to $6.26 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 5.42 percent.
Moreover, the firm recently paid out its quarterly dividend on 09/28/2023. Investors who held shares on 09/15/2023 were paid a $0.75 dividend. On an annualized basis, this represents a $3.00 dividend and a 3.95% percent yield. There was an ex-dividend date of 09/14/2023 for this dividend. In terms of dividend payout ratio, GILD is presently at 67.60%.
Gilead Sciences Inc.(GILD) Company Profile
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Merck & Co, Inc. and Tentarix Biotherapeutics Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
